Projecting future complications of chronic hepatitis C in the United States

Davis, Gary L.

doi:10.1053/jlts.2003.50073

Cited by 538 publications

(391 citation statements)

References 40 publications

Supporting

Mentioning

375

Contrasting

Unclassified

Order By: Relevance

“…[27–30] In the absence of new treatments that would reverse liver damage, the primary intervention that could effectively reduce the health impact of HCV infection in the US is antiviral therapy. Davis et al[28] estimated that the risk of liver-related death could be reduced by 36% with current peginterferon-based therapy, but only if all infected patients were treated.…”

Section: Discussionmentioning

confidence: 99%

Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

Kauf

Mohamed

Hauber

et al. 2012

Patient-Patient-Centered-Outcome-Res

View full text Add to dashboard Cite

BackgroundSome patients with chronic hepatitis C virus (HCV) infection forego treatment due to concerns about treatment efficacy, treatment duration, and side effects.ObjectiveThe purpose of this study was to quantify patient preferences among possible outcomes associated with new, direct-acting antiviral agents (DAAs) for the treatment of HCV infection and determine which treatment features are most important to patients in making treatment decisions.MethodsAdult participants with a self-reported physician diagnosis of HCV infection in five countries completed a web-enabled, choice-format conjoint analysis survey. The survey presented participants with 20 treatment-choice questions. Each treatment-choice question included a pair of hypothetical treatment profiles with varying levels of six attributes: treatment duration; chance of getting rid of the virus completely (i.e. likelihood of a sustained virologic response [SVR]); weeks on an additional, third medicine (i.e. a DAA); risk of a severe rash; risk of severe anemia; and number of times a day the third medicine is taken. Treatment-choice questions were based on a predetermined experimental design with known statistical properties. Random-parameters logit was used to estimate preference weights for all attribute levels and the mean relative importance of each attribute.Results284 participants completed the survey. Likelihood of an SVR was the most important outcome to participants, followed by severe anemia risk, severe rash risk, therapy type (a combination of total weeks of treatment and weeks on the third medicine), and dosing of the third medicine. Controlling for other factors, preferences were similar across all therapy types examined.ConclusionPatients with HCV infection indicate a willingness to accept an increased risk of side effects for sufficient improvement in the likelihood of treatment response.Electronic Supplementary MaterialSupplementary material is available for this article at 10.1007/BF03262498 and is accessible for authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

Kauf

Mohamed

Hauber

et al. 2012

Patient-Patient-Centered-Outcome-Res

View full text Add to dashboard Cite

show abstract

“…The mean liver biopsy length was 2.0 ± 0.9 cm (range 0.9 -5.3 cm). The mean number of complete portal tracts available for assessment was 10 ± 4 (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Stage of fibrosis was noted as 0 to 1 (40%), 2 to 3 (20%), and 4 (40%).…”

Section: Patient and Volunteer Demographics And Diagnosesmentioning

confidence: 99%

“…As the second leading gastrointestinal cause of death following colorectal cancer, cirrhosis accounts for an estimated 44,000 deaths, 150,000 acute care hospitalizations, and $1.1 billion in direct costs annually in the United States (1,2). Furthermore, these trends are expected to increase, based on an aging population, the growing epidemic of obesity and its complications (non-alcoholic fatty liver diseases, NAFLD), and the continued emergence of chronic liver diseases and its complications among individuals with long-standing chronic hepatitis C infection (3,4).…”

Section: Introductionmentioning

confidence: 99%

Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography

Yin

Talwalkar

Glaser

et al. 2007

Clinical Gastroenterology and Hepatology

856

809

View full text Add to dashboard Cite

Background & Aims-Accurate detection of hepatic fibrosis is crucial for assessing prognosis and candidacy for treatment in patients with chronic liver disease. Magnetic Resonance (MR) Elastography, a technique for quantitatively assessing the mechanical properties of soft tissues, has previously been shown to have potential for non-invasively detecting liver fibrosis. The goal of this work was to obtain preliminary estimates of the sensitivity and specificity of the technique in diagnosing liver fibrosis, and to assess its potential for identifying patients who can potentially avoid biopsy.

show abstract

“…2 Furthermore, these trends are expected to increase based on an aging population, the growing epidemic of obesity, and the continued emergence of clinical manifestations among individuals with longstanding chronic hepatitis C infection. 3,4 In terms of patients as well as populations, there remains a great need to develop and identify methods of risk stratification and prognosis for individuals with chronic liver disease. To date, the noninvasive diagnostic tests available from clinical practice are not sensitive or specific enough to function as screening tests for detecting occult yet significant liver injury.…”

mentioning

confidence: 99%

Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications

et al. 2008

View full text Add to dashboard Cite

Chronic liver disease and cirrhosis remains a major public health problem worldwide. While the majority of complications from chronic liver disease result from progressive hepatic fibrosis, the available diagnostic tests used in clinical practice are not sensitive or specific enough to detect occult liver injury at early or intermediate stages. While liver biopsy can stage the extent of fibrosis at diagnosis, its utility as a tool for longitudinal monitoring will be limited at the population level. To date, a number of methods including serum marker panels and ultrasound-based transient elastrography have been proposed for the non-invasive identification of hepatic fibrosis. Novel techniques including magnetic resonance (MR) spectroscopy, diffusion weighted MR, and MR elastography have also emerged for detecting fibrosis. In contrast to other non-invasive methods, MR imaging holds the promise of providing functional and biological information about hepatic pathophysiology as it relates to the natural history and future treatment of hepatic fibrosis. (HEPATOLOGY 2008;47:332-342.)

show abstract

Projecting future complications of chronic hepatitis C in the United States

Abstract: Chronic hepatitis C virus (HCV) infection is common and

Cited by 538 publications

References 40 publications

Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography

Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications

Contact Info

Product

Resources

About